|
🐜
|
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
17 auth.
T. King,
W. Bradford,
S. Castro-Bernardini,
E. Fagan,
I. Glaspole,
M. Glassberg,
E. Gorina,
P. Hopkins,
D. Kardatzke,
L. Lancaster,
...
D. Lederer,
S. Nathan,
C. Pereira,
S. Sahn,
R. Sussman,
J. Swigris,
P. Noble
|
10 |
2014 |
10
🐜
|
|
🐜
|
Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure
25 auth.
A. Demetriou,
Robert S. Brown,
R. Busuttil,
J. Fair,
B. McGuire,
P. Rosenthal,
J. S. am Esch,
J. Lerut,
S. Nyberg,
M. Salizzoni,
E. Fagan,
B. de Hemptinne,
C. Broelsch,
M. Muraca,
J. Salmerón,
...
J. Rabkin,
H. Metselaar,
D. Pratt,
M. L. de la Mata,
L. McChesney,
G. Everson,
P. Lavin,
A. Stevens,
Z. Pitkin,
B. Solomon
|
9 |
2004 |
9
🐜
|
|
🐜
|
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials
17 auth.
P. Noble,
C. Albera,
W. Bradford,
U. Costabel,
R. D. du Bois,
E. Fagan,
R. Fishman,
I. Glaspole,
M. Glassberg,
L. Lancaster,
...
D. Lederer,
J. Leff,
S. Nathan,
C. Pereira,
J. Swigris,
D. Valeyre,
T. King
|
8 |
2016 |
8
🐜
|
|
🐜
|
Prospective study of bacterial infection in acute liver failure: An analysis of fifty patients
9 auth.
N. Rolando,
F. Harvey,
J. Brahm,
J. Philpott‐Howard,
G. Alexander,
A. Gimson,
...
M. Casewell,
E. Fagan,
Roger Williams
|
8 |
1990 |
8
🐜
|
|
🐬
|
SERUM AMYLOID-A PROTEIN CONCENTRATION IN INFLAMMATORY DISEASES AND ITS RELATIONSHIP TO THE INCIDENCE OF REACTIVE SYSTEMIC AMYLOIDOSIS
F. C. de Beer,
E. Fagan,
G. Hughes,
R. Mallya,
J. Lanham,
M. Pepys
|
7 |
1982 |
7
🐬
|
|
🐜
|
Fungal infection: a common, unrecognised complication of acute liver failure.
8 auth.
N. Rolando,
F. Harvey,
J. Brahm,
J. Philpott‐Howard,
G. Alexander,
M. Casewell,
...
E. Fagan,
Roger Williams
|
7 |
1991 |
7
🐜
|
|
🐜
|
Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis
7 auth.
W. Carman,
E. Fagan,
S. Hadziyannis,
Peter Karayianni,
N. Tassopoulos,
Roger Williams,
...
H. Thomas
|
7 |
1991 |
7
🐜
|
|
🐜
|
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
19 auth.
S. Nathan,
C. Albera,
W. Bradford,
U. Costabel,
R. D. du Bois,
E. Fagan,
R. Fishman,
I. Glaspole,
M. Glassberg,
Kenneth F Glasscock,
...
T. King,
L. Lancaster,
D. Lederer,
Zhengning Lin,
C. Pereira,
J. Swigris,
D. Valeyre,
P. Noble,
A. Wells
|
7 |
2016 |
7
🐜
|
|
🐜
|
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
10 auth.
C. Albera,
U. Costabel,
E. Fagan,
M. Glassberg,
E. Gorina,
L. Lancaster,
...
D. Lederer,
S. Nathan,
D. Spirig,
J. Swigris
|
7 |
2016 |
7
🐜
|
|
🐜
|
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
17 auth.
L. Lancaster,
C. Albera,
W. Bradford,
U. Costabel,
R. D. du Bois,
E. Fagan,
R. Fishman,
I. Glaspole,
M. Glassberg,
T. King,
...
D. Lederer,
Zhengning Lin,
S. Nathan,
C. Pereira,
J. Swigris,
D. Valeyre,
P. Noble
|
6 |
2016 |
6
🐜
|
|
🦁
|
Multiorgan granulomas and mitochondrial antibodies.
E. Fagan,
J. Moore-Gillon,
M. Turner‐Warwick
|
6 |
1983 |
6
🦁
|
|
🐬
|
Detection of hepatitis B virus DNA in spermatozoa, urine, saliva and leucocytes, of chronic HBsAg carriers. A lack of relationship with serum markers of replication.
F. Davison,
G. Alexander,
R. Trowbridge,
E. Fagan,
Roger Williams
|
6 |
1987 |
6
🐬
|
